Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2023-10-26 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a change in shareholder equity percentage for a specific shareholder (HH SPR XIV HK Holdings Limited) in the company 益方生物科技（上海）股份有限公司. It details the shareholding before and after the change, the method of change (block trade), and confirms no change in controlling shareholder or governance structure. It references compliance with securities laws and disclosure obligations. The document is short (1785 characters) and focuses solely on notifying the market of a change in major shareholding percentage, without financial statements or management discussion. This fits the definition of a Major Shareholding Notification (MRQ).
2023-10-26 Chinese
益方生物2023年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the "2023 Second Extraordinary General Meeting of Shareholders" of Yifang Bio-Technology (Shanghai) Co., Ltd. It contains detailed meeting instructions, agenda, and proposals for shareholder approval, including changes to investment projects, auditor appointment, and director election. The content is focused on the meeting process and proposals to be voted on, typical of materials provided for a shareholder meeting. The document length is 3999 characters, which is relatively short and consistent with meeting materials rather than a full report. There is no financial data or results presented, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a voting results announcement since it does not provide voting outcomes. The document is clearly the meeting materials for the shareholders' meeting, which fits the definition of AGM Information (AGM-R).
2023-10-24 Chinese
益方生物关于持股5%以上股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged, the proportion of total shares, and the pledgee information. This type of disclosure is related to share pledges and financing arrangements involving shareholders' shares. It is not a full financial report, earnings release, or management discussion. It is not a voting result or AGM material. The content fits best under Capital/Financing Update (CAP) as it concerns financing activities related to share pledges by a significant shareholder.
2023-10-17 Chinese
益方生物独立董事关于公司第一届董事会2023年第五次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several board meeting proposals, including changes to fundraising investment projects, director election, and auditor appointment. It references the company's board meeting and legal compliance but does not contain financial statements or detailed financial data. The document is a formal opinion related to board/management decisions rather than a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on governance and board matters, not an annual or interim report or audit report.
2023-10-13 Chinese
益方生物关于拟变更会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement by a company about its intention to change its auditor for the upcoming fiscal year. It details the new auditor's qualifications, the reasons for the change, communication with the previous auditor, and the approval process by the board and independent directors. The document does not contain any financial statements or audit reports themselves, but rather is a formal announcement regarding the change of the audit firm. The document length is 3589 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this fits best under the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. However, since it is specifically about the change of auditor and includes detailed audit-related information, it is more appropriate to classify it as Audit Report / Information (AR) rather than a Regulatory Filing (RNS). FY 2023
2023-10-13 Chinese
益方生物独立董事关于公司第一届董事会2023年第五次会议相关议案的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on proposals related to the company's 2023 fifth board meeting, specifically about changing the 2023 audit firm. It references compliance with company law and stock exchange listing rules. The document is short (743 characters) and does not contain financial data or detailed audit results, but rather an opinion on a board proposal. This fits the category of Board/Management Information (MANG), as it concerns board meeting proposals and approvals related to management decisions, not a full audit report or annual report.
2023-10-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.